Latest Conference Content

Duke Appiah, PhD, MPH, explores racial disparities in maternal health outcomes for pregnant women with cancer, revealing critical insights for informed decision-making.

Experts champion medically integrated care and oncology optimized distribution models as vital strategies to improve outcomes, streamline access, and reduce costs for patients.

Experts urge for technology-driven, collaborative solutions as patients shoulder a growing burden of prescription costs.

Experts emphasize the need for enhanced clinical trial infrastructure in community oncology to ensure equitable access to innovative therapies for all patients.

Improving health equity is part of the core of quality improvement and requires data collection and community engagement strategies for underserved populations, said Shawn Griffin, MD, president and CEO of URAC.

Key trends and challenges are shaping the next era of advanced therapies, from FDA momentum to broader patient access.

Strategic relationships and feedback can enhance specialty pharmacy operations, said Natalie Bedford, senior vice president of US pharmaceutical distribution services at McKesson.

Balancing technology and patient care can enhance communication and data collection, improving adherence and outcomes in specialty pharmacy, said Kathi Henson, MBA, of Orsini.

Mike Fazio, director of value-based care at Navista, Cardinal Health, discusses a trending topic at the 2025 Community Oncology Conference: optimizing oncology care with technology.

Results presented on Tuesday at the American Association for Cancer Research annual meeting include data on the combined use of tissue and liquid biopsy, as well as a framework for evaluating multicancer early detection testing.

Oncology leaders from Alliance Cancer Specialists, American Oncology Network, CHI St. Vincent, Memorial Sloan Kettering Cancer Center, and New York Cancer & Blood Specialists discussed the power of collaboration in cancer care, highlighting partnerships that enhance patient outcomes and resource sharing in community practices.

At Asembia’s AXS25 Summit, industry experts explored how pharmacy is evolving to meet rising patient expectations and navigate a shifting health care environment.

Mingyang Song, MBBS, ScD, discusses the link between ultraprocessed foods and cancer risk, emphasizing nutrition's role in prevention.

K. "Vish" Viswanath, PhD, explores the evolution of health misinformation, its sources, and the role of technology in shaping public understanding.

Evaluating the impact of the Inflation Reduction Act (IRA) will require real-time data and effective therapy metrics, explained H. John Beardsley, MBA, of CoverMyMeds; and Fauzea Hussain, MPH, of McKesson.

Raymond Osarogiagbon, MD, discusses the challenges of implementing lung cancer screening guidelines and the need for increased awareness and access.

With artificial intelligence (AI) capabilities freeing up workers and driving billions in gains, pharmacy may soon see a 75% workload drop.

Early actions by the new administration signal major changes in health policy, taxes, and pharmaceutical pricing.

Prior studies have shown that women may absorb cancer therapies differently than men, but this study focused on the fallout on patients' physical activity and quality of life.

From a meeting that celebrates basic research and being "first," a look at 3 data sets on therapies that would break new ground.

Kimlin Tam Ashing, PhD, of City of Hope National Medical Center, emphasizes the vital role of community engagement in cancer research, enhancing trust and communication between scientists and communities.

Zongertinib shows promise for treating HER2-mutant non–small cell lung cancer (NSCLC), with significant activity against brain metastases and low interstitial lung disease risk, explains John Heymach, MD, PhD.

Artificial intelligence (AI) has the potential to deliver personalized nutrition; however, there is a need for professional oversight, emphasized Julia Logan, BS.

Results could give patients with HER2-mutated non–small cell lung cancer (NSCLC) an oral therapy option.

John Heymach, MD, PhD, The University of Texas MD Anderson Cancer Center, discusses the promising results of zongertinib for HER2-mutated non–small cell lung cancer, showcasing high response rates and improved patient quality of life.

The session follows the American Association for Cancer Research's (AACR) prior call to action against executive orders that would harm the National Institutes of Health.

Julia Logan, BS, discusses the vital role of nutrition in cancer care, highlighting how artificial intelligence can enhance dietary recommendations for patients.

Luis Carvajal-Carmona, PhD, stresses the importance of global collaboration in cancer research to enhance understanding and treatment across diverse populations.

Ravindra Uppaluri, MD, PhD, lead investigator of the phase 3 KEYNOTE-689 trial (NCT03765918), highlights the need for a multidisciplinary approach to translate the study's findings into real-world care for patients with resectable head and neck cancer.

Dostarlimab effectively eliminates the need for surgery in patients with advanced mismatch repair–deficient tumors in renal cancer, enhancing quality of life.